Adoption of Subcutaneous Immunotherapy in Advanced Melanoma Practice

This segment explores real-world adoption of subcutaneous immunotherapy in advanced melanoma, focusing on both patient and clinical perspectives. Dr. Morrison transitions the discussion toward day-to-day treatment experience, prompting Ms. Haupert to reflect on being among the early patients at her center to receive subcutaneous administration. She describes a mix of excitement and uncertainty but emphasizes her willingness to pursue an option that could improve her quality of life and reduce treatment burden. Dr. Morrison contextualizes this experience by noting that subcutaneous administration involves the same established therapy delivered through a different route, which can help ease concerns about trying a newer approach. He also shares insights from clinical practice, explaining that many patients are being transitioned to subcutaneous administration when appropriate, while acknowledging that treatment decisions may still vary based on individual clinical scenarios.